

Gene Logic's Aspiration – To be the Most Valued Biology Partner to the Pharmaceutical Industry

a report by

Gene Logic Inc.

Your Chemistry. Our Biology. Your Success.

Gene Logic's partnership-based philosophy has guided our emergence as a leading provider of products and services across all three major segments of the drug development chain – drug discovery, pre-clinical and clinical. Our clients have driven our evolution, and meeting their needs continually brings us closer to fulfilling our aspiration – to be the most valued biology partner to the pharmaceutical industry.

Our range of discovery subscription products and services – such as our BioExpress® and ToxExpress® Systems – are widely used by the majority of leading names in the pharmaceutical industry. Our BioExpress® System, built on over 18,000 extensively annotated human clinical samples, enables clients to analyse genes and gene expression profiles as an integral part of their drug development programmes. Our ToxExpress® System, with over 12,000 samples analysed from well-characterised reference compounds and proprietary prediction algorithms, help industry leaders screen and identify lead compounds most likely to succeed in development and uncover the molecular cascade leading to adverse events and potential safety biomarkers.

Our 2002 acquisition of TherImmune Research Corporation has provided Gene Logic with resources and expertise in drug discovery and pre-clinical activities. Gene Logic operates full pre-clinical GLP laboratories, with small and large animal facilities. Our laboratories provide services across species and routes of administration, backed by proven expertise in analytical services and regulatory compliance. More than 1,200 studies have been completed on behalf of clients, ranging from general toxicology, reproductive and developmental toxicology, safety pharmacology and carcinogenicity.

To complement and leverage these capabilities, Gene Logic has added an important new capability – the Drug Repositioning and Selection™ Programme. The acquisition of the drug repurposing platform of Millennium Pharmaceuticals gives Gene Logic leading technologies in rescuing and repositioning

failed or struggling compounds. These efforts are aimed at returning these compounds to successful clinical development. Given the rising costs and lengthening time to bring a drug to market, clients must make the best possible use of every research and development investment. By thinking as a partner – listening to clients and understanding their needs – Gene Logic has taken important steps designed to provide clients with the insights and expertise needed to find the full therapeutic and commercial potential within each drug in the developmental pipeline.

Gene Logic also provides a broad suite of Clinical Pharmacogenomic capabilities. Our team of clinicians, biostatisticians, regulatory experts and scientists offers complete pharmacogenomic solutions to improve this critical phase of drug development, offering expertise in patient stratification, biomarker identification and *in vivo* Mechanism of Activity, clinical and regulatory consulting, and a proprietary method for processing and analysing whole blood.

Gene Logic's approach to doing business – a partnership approach, based on finding the developmental solutions critical to the success of each drug, and each client – has driven us to grow and expand our resources, our technologies and our areas of expertise. Today, Gene Logic's portfolio of products and services reflects a commitment to more than monetary investment. It is practical proof of our aspiration to be the most valued partner to the pharmaceutical industry. Our current roster of offerings covers this entire spectrum:

- Genomics and Toxicogenomics:
 - BioExpress® System;
 - ASCENTA™ System;
 - ToxExpress® System;
 - ToxScreen™ Reports;
 - Mechanism of Toxicity (MOT) reports;
 - Genesis Enterprise System™ software; and
 - Microarray Data Generation and Analysis Service.
- Preclinical Services:
 - General Toxicology;
 - Reproductive and Developmental Toxicology;

- Safety Pharmacology;
 - Bioanalytical Services;
 - Pathology Services;
 - Clinical Pathology Services; and
 - Carcinogenicity.
- Drug Repositioning and Selection™ Programme:
 - Indication Seeking Partnerships;
 - Drug Repositioning and Rescue Partnerships; and
 - Compound Selection for Compounds Entering Pre-clinical Development.
 - Clinical Solutions:
 - Patient Stratification Partnerships;
- Biomarker Identification and *in vivo* Mechanism of Activity; and
 - Clinical and Regulatory Consulting. ■

Contact Information

Gene Logic Inc.
610 Professional Drive
Gaithersburg, Maryland 20879
Tel.: +301 987 1700
Fax: +301 987 1701
e-Mail: info@genelogic.com
www.genelogic.com